Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...

Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...

(RTTNews) - Gilead Sciences Inc. (GILD) announced that the European Commission has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis in ...

U.S. Indication for Livdelzi Livdelzi is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate ...

Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...